Gd2Aussie3
17 년 전
Ronnies...Don't blame you. With ENCY you lucked out and had some profit. Hopefully your next endeavor is much, much better.
Here are two companies that have really good products and, IN MY OPINION, great potential. It's the potential and their customer base you want to look at. I have included their websites for your DD and convenience.
PureDepth ™
http://www.puredepth.com/
Signalife Clear Data
http://www.signalife.com/index.asp
SGN went up $.14 yesterday; but, don't let that fool you. It has done that before. Presently, their charts, in a word, suck.
G' day Mate,
Aussie
Gd2Aussie3
17 년 전
UPDATE 1-Pfizer says to buy Encysive and Thelin lung drug --Wed Feb 20, 2008 11:10am ET
By Ransdell Pierson
NEW YORK, Feb 20 (Reuters) - Pfizer Inc (PFE.N: Quote, Profile , Research) on Wednesday said it has agreed to pay about $195 million to acquire Encysive Pharmaceuticals Inc (ENCY.O: Quote, Profile , Research) and its Thelin lung-disorder medicine that has repeatedly failed to win U.S. approval.
Pfizer, which badly needs new medicines to offset sales declines for its drugs facing generic competition, said it will make a cash offer for all Encysive shares at $2.35 apiece, for an equity value of $195 million. That is more than double Encysive's closing share price on Tuesday of $1.08.
Pfizer said it has also agreed to assume Encysive's change of control repurchase obligations under its 2.5 percent convertible senior notes.
The U.S. Food and Drug Administration has issued three approvable letters for Thelin, which is used to treat pulmonary arterial hypertension, without allowing it to come to market.
The often-fatal condition is characterized by very high blood pressure in the arteries between the lungs and heart and is estimated to affect about 100,000 people in North America and Europe.
"Pfizer plans to conduct a pivotal Phase III trial to support registration in the U.S." of Thelin, Pfizer said in its release, noting that the drug is already approved in the European Union, Australia and Canada.
Thelin is a once-daily pill that works through a different mechanism than Pfizer's own approved Revatio treatment for pulmonary arterial hypertension.
The Encysive drug blocks receptors to the protein endothelin that causes a tightening of blood vessels.
Revatio, which has the same active ingredient as Pfizer's widely used Viagra anti-impotence treatment, relaxes smooth muscle cells lining blood vessels and thereby improves blood flow to particular areas of the body.
"The acquisition of Encysive will add growing, near-term revenue from the European market and increase our already strong presence in the cardio-respiratory arena with a product that complements Revatio," said Ian Read, Pfizer's president of pharmaceutical operations.
Shares of Swiss drugmaker Actelion (ATLN.VX: Quote, Profile , Research), whose marketed Tracleer drug is a rival treatment for the lung condition, fell as much as much as 3.3 percent after Pfizer announced its intention to buy Encysive.
"Actelion is coming off on this because (the) market was speculating Pfizer could bid for Actelion and one might see Pfizer's marketing power as a threat to Tracleer," one trader said.
Pfizer shares were little changed in morning trading on the New York Stock Exchange, amid a moderate downturn for the drug sector. Encysive shares soared 110 percent, or $1.19, to $2.27, on the Nasdaq.
--------------------------
G' day Mates,
Aussie
florida135
17 년 전
ronnies, you could be right. Otherwise, why would a stock that's going to be worth $2.35 in a month or two, be selling down to this price of $2.26 instead of being bought for a nice sized profit ???? Each 1 million shares nets a cool profit of $10,000, and buying it here would net each buyer of 1 million shares a $90,000 gain. Not too bad for a short term investment is it. How they managed to get it down this low after the news is puzzling to me. As we get closer and closer to the final date, this stock has to go higher. Regards, Florida
florida135
17 년 전
ronnies, from the way this news release was worded, it looks like both sides feel like this is a done deal !!!! Florida Pfizer to buy Encysive for $195 million
Marketwatch - February 20, 2008 11:33 AM ET
BOSTON (MarketWatch) -- Pfizer Inc., the world's largest drugmaker, said early Wednesday that it has entered into a deal to acquire troubled Texas-based biotech Encysive Pharmaceuticals for $195 million in cash in a move that would give it a larger foothold in the cardiovascular-respiratory drug market.
Pfizer (PFE) said that it has agreed to pay $2.35 a share for Encysive, whose stock closed at $1.08 on Tuesday. The offer has been unanimously approved by Encysive's board.
scstocks
17 년 전
Hello hoop, I just went back and read that post where you mentioned you were sitting on shares from .73, back on Jan 22.
In that post you wrote: "Waiting for buyout/partnership to launch..."
I am curious as to what, if anything, had you feeling that the company might be a target. I forgot if they had announced that they were shopping the company or not????
The reason I ask, is that I have a good amount of SNUS, and they have announced that might have an interest in being acquired, or some such language, in their last cc, as well as a large, relative, cash position. So I am wondering if you heard similar language with ENCY?
One can always hope
Take Care.
Hoop
17 년 전
February 19, 2008
�� Upgrading ENCY to BUY
We recently attended the 4th World Symposium on Pulmonary
Hypertension where we were, admittedly, surprised by the seeming
positivity of European physician sentiment on Thelin. As a result, we are
upgrading ENCY’s shares to BUY and instituting a price target of $3.
�� Positive Feedback on EU Sales Force
By and large, physicians viewed Thelin and Tracleer as interchangeable –
with some slight edge going to Thelin when patients are receiving
concomitant PDE-5 therapy (recall the symbiotic relationship between
Thelin and sildenafil). While Tracleer sales certainly seem “sticky,” in our
view, the increased usage of Thelin coupled with an impressively strong
and well regarded European sales force (reminiscent of TKT’s vaunted 5S
group), may well result in Encysive finding the wanting gaze of lovelorn
third party (belated Valentine’s Day wishes), particularly a company
lacking a strong European infrastructure in the PAH space itself.
�� A Spot for Thelin in the US
Moreover, while US physician sentiment remains split, and the sour taste
of the FDA debacle has yet to dissipate, it is important to note that the
widespread view (ours included) is if one properly executed trial is run,
Thelin will eventually garner US approval. Moreover, if it is priced at a
discount to the other ETRAs, there is, in fact, a spot for it on the US
market. Even if it is not, there are sufficient new patient diagnoses, and
the ETRAs are so difficult to differentiate, that physicians will have
“favorites,” and clever marketing by whoever owns Thelin at the time can
result in the drug finding its niche.
�� Risks and Valuation
Encysive’s current Enterprise Value (using fully diluted shares including
converts) is approximately $84MM, fully supported, we believe, by Thelin’s
current European sales trajectory alone. If one assumes $100MM in sales
are achievable in 4 years time, and applies a 4x multiple, discounting back
at 20% per annum, Thelin sales are currently worth $192MM. This
excludes the value of the company’s European infrastructure as well as
the fact that Encysive is, in our opinion, only one successful trial away from
garnering Thelin approval in the US. When taken in its entirely, a take out
at 1.5x EV, or $1.30, seems entirely justifiable. We believe the Enterprise
Value plus the inherent value of the European sales force therefore yields
our price target of $3. Risks include continued delays in Thelin’s approval
process. Refer to the company’s SEC filings for greater detail of risks.
Contact
Andrew S. Fein
(212) 389-8045
afein@collinsstewartLLC.com
Hoop
17 년 전
Logical post from another board:
The next earnings report out will be for Q4 2007. Projected Thelin sales are less than $5 million.
There is much more potential for a higher level of operational expenses, as the sales force is ramped up, than a positive surprise to the bottom line. I am bullish on the stock, and think the long-term sales picture for Thelin is available for an exceptional value right now (buy the stock!), but I would not predict any positive earnings report from current sales.
I will look carefully at the operational expenses in the next report. I expect the sales force expenses to rise. I hope the R&D is significantly lower, as well as administartive costs. There could still be some charges, against employee severances.
It is a difficult time for ENCY. They can make it as a stand alone pharmaceutical company, but the next year will be so lean that it will not support the R&D budget that they have gotten accustomed to. But they have only 2 choices: extreme belt-tightening and organic growth of Thelin revenues, or merger/acquisition. I would think the poster who suggested dilution, is sugggesting something impossible. ENCY is already a sub-$1 stock, low market cap, NASDAQ delisting candidate. Possibly some combination of dilution/reverse split, MIGHT allow a temporary cash flow that wouild be welcome, but it more likely would lead to delisting and failure.
I fully expect to check Yahoo one morning and see a white knight takeover proposal. This company does not want to cut the R&D (and they do have several promising drug candidates in advanced studies). They have brought in Morgan Stanley, as a selling agent, and they have pursued the Thelin ramp-up with a vengeance. But they are unlikely to surprise with earnings upside, as they are most likely lagging in the expense cutting (waiting a little longer, hoping on a white knight), and spending on the sales roll-out of Thelin.
scstocks
17 년 전
Press Release Source: Encysive Pharmaceuticals Inc.
Encysive Pharmaceuticals Announces Presentation of Sitaxsentan Data in Eisenmenger Syndrome At AHA Meeting
Monday November 5, 5:00 pm ET
HOUSTON, Nov. 5, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals, Inc. (NasdaqGM:ENCY - News) today announced that open label observational data from Columbia University suggests that sitaxsentan (THELIN), a selective endothelin A receptor antagonist, may improve symptoms associated with Eisenmenger syndrome (ES). The analyses were presented today at the American Heart Association (AHA) Scientific Sessions 2007 meeting in Orlando.
ADVERTISEMENT
A retrospective chart review was performed on 14 consecutive ES patients (10 females, 4 males; age 27 +/- 11 years) initiating open label sitaxsentan therapy (100 mg tablets daily) at Columbia University between 2002 and 2006. Baseline data were compared to short- and long-term follow-up data at 12 weeks and at approximately one year. There was a significant decrease in the pulmonary vascular resistance (PVR) to systemic vascular resistance (SVR) ratio, consistent with pulmonary selectivity in these patients. The improvements in PVR index and six-minute walk distance were not significant. During the one-year follow-up, these ES patients had no significant change in resting systemic arterial oxygen saturation.
``These results suggest that treatment with sitaxsentan is safe and efficacious in patients with Eisenmenger syndrome,'' commented Dr. Robyn J. Barst, Professor of Pediatrics at Columbia University College of Physicians and Surgeons, and Director, New York Presbyterian Hospital Pulmonary Hypertension Center.
About Eisenmenger Syndrome
Eisenmenger syndrome is a progressive cardiovascular condition that can develop in individuals who have un-repaired congenital heart defects. ES is initially associated with increased pulmonary blood pressure that, if the congenital heart defect(s) is not repaired, results in reversal of the shunt from left to right to right to left with progressive pulmonary vascular disease and progressive cyanosis. ES is linked to multi-organ damage and premature death. There is currently no cure for ES once it is established.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com.
The Encysive Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=843
This press release contains ``forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are decisions by the U.S. Food and Drug Administration regarding whether and when to approve our drug application for THELIN (sitaxsentan sodium), our ability to raise capital to fund cash requirements for future operations, timelines for initiating new trials and completing ongoing clinical trials for sitaxsentan sodium (THELIN), our estimates of the sufficiency of our existing capital resources, as well as more specific risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Contact:
Encysive Pharmaceuticals
Investors:
Ann Tanabe, VP, Investor Relations and Corporate
Communications
(713) 796-8822
The Trout Group
Marcy Strickler
(646) 378-2927
BMC Communications
Media:
Dan Budwick
(212) 477-9007 ext. 14
Hot Features
프리미엄
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
The_Free_Nebula
17 년 전
